Amarin loss widens; Cancer docs hardest for sales reps to see; Teva gets EC go-ahead for Lonquex;

@FiercePharma: Allergan joins the patent-loss party in India: Board revokes patents on Ganfort, Combigan glaucoma meds. Report | Follow @FiercePharma

@EricPFierce: Onyx CEO insists there are multiple players at buyout poker table. Reports had said Amgen sat alone. Story | Follow @EricPFierce

@CarlyHFierce: Incredulity turns to praise as malaria vax posts positive PhI data. More from FierceVaccines | Follow @CarlyHFierce

> Amarin ($AMRN) reported a larger loss for the second quarter of the year, despite sales of $5.5 million from its new cholesterol-lowering medicine Vascepa. Story

> Teva Pharmaceutical Industries ($TEVA) has gotten authorization from the European Commission to market Lonquex (lipegfilgrastim) for treating neutropenia and the incidence of febrile neutropenia in some adults getting chemotherapy. Release

> Actavis ($ACT) has gotten approval from French authorities for its acquisition of Warner Chilcott ($WCRX). Item

> A lawsuit has been filed against a law in Oklahoma that bans girls under the age 17 from getting Teva's morning-after contraceptive pill. Story

> A grant may help developers get to the market by 2015 with a smart pill bottle that notifies patients to take their meds. Story

Medical Device News

@FierceMedDev: Zimmer owes Stryker $228M in patent lawsuit. News | Follow @FierceMedDev

@DamianFierce: Meet Verizon Wireless, medical device manufacturer. Story | Follow @DamianFierce

@MichaelGFierce: GE, U. of Wash. team up to make paper-based diagnostics device. Article | Follow @MichaelGFierce

> Alere wins FDA nod for HIV test, struggles on the Street. Report

> SightLine raises $107M fund for med tech investments. Item

Biotech News

@FierceBiotech: Popular yesterday: Upsized Intrexon IPO delivers another blockbuster success for billionaire Kirk. Story | Follow @FierceBiotech

@JohnCFierce: Over the past month 7 biotechs have raised $562M from IPOs. Brings the year's total so far to more than $2B. | Follow @JohnCFierce

@RyanMFierce: Ariad Pharma denied FDA's coveted 'breakthrough' stamp for lung cancer drug. News | Follow @RyanMFierce

@EmilyMFierce: NIH and Lacks family decision to open genomic data of HeLa cells to researchers will also establish genome database. Article | Follow @EmilyMFierce

> FDA deals Novo Nordisk another setback for hemophilia therapy. Report

> Is the biotech IPO frenzy headed for a crack-up? Editor's Corner

And Finally... A study finds that for the second year in a row, oncologists are the hardest doctors for pharma sales reps to get facetime with. Story

Suggested Articles

Which rollouts might suffer most? Those that treat chronic diseases, require doctors to administer them or face current competition, analysts say.

Novartis and Incyte will put their blockbuster JAK inhibitor into phase 3 clinical trials as a possible treatment for COVID-19, the drugmakers said.

The Cannes Lions canceled its advertising creativity conference for 2020 after media reports that many large ad agencies planned to opt out.